Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol

American Journal of Preventive Cardiology(2020)10.1016/j.ajpc.2020.100012Source: DataRank Database

Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol is a research paper published in American Journal of Preventive Cardiology (2020). On theSindex it has a DataRank of 0. It has been cited 24 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.74)OA: goldTopics (16)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Joshua Miles ORCID,Carlota Oleaga ORCID,Om P. Ganda ORCID,P. Barton Duell ORCID,Jonathan Q. Purnell ORCID

Live enrichment

PubMed:34327453 PMC:PMC8315390 OpenAlex:https://openalex.org/W3021337500

National Institutes of Health

Grant: K12HD043488

National Institutes of Health

Grant: RO1 5R01HL132985

National Institutes of Health

Grant: RO1 P30DK36836

NIDDK NIH HHS

Grant: P30 DK036836

NHLBI NIH HHS

Grant: R01 HL132985

FWCI

2.74

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ajpc.2020.100012

publisherhttps://doi.org/10.1016/j.ajpc.2020.100012

publisherhttps://api.elsevier.com/content/article/PII:S266666772030012X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S266666772030012X?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34327453

Fields of Study

Lipoproteins and Cardiovascular HealthCoronary Interventions and DiagnosticsCerebrovascular and Carotid Artery Diseases

Keywords

MedicinePCSK9Internal medicineClinical trialGastroenterologyLipoproteinLDL receptorCholesterolLDLDyslipidemiaPharmacotherapyLipid-lowering TherapyProprotein Convertase Subtilisin/kexin Type 9 Inhibitor

Sustainable Development Goals

SDG 0: Reduced inequalities